International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London. At the two-day "Optimising Stability Testing" conference Dr Sven Oliver Kruse, managing director of Diapharm Analytics GmbH (www.diapharm.com), was one of those explaining how the burden of ongoing stability tests can be reduced with improved study design. - October 01, 2008 - Diapharm

Anavex completes successful preclinical studies on Anavex 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease. - September 04, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences presented its new findings of its ANAVEX 1-41 compound targeting Alzheimer's disease at ICAD (July 26 to 31, 2008). - August 02, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) announces its participation at the International Conference on Alzheimer's Disease 2008 (July 26-31, 2008, Chicago, USA), where it will present results obtained with Anavex 1-41 demonstrating a protective effect against the neurotoxicity of... - July 15, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced the appointment of David L. Tousley, CPA, MBA, to its Board of Directors. Mr. Tousley is an accomplished professional with many years of experience as a senior financial and operations executive in start-up and established... - June 20, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ("ANAVEX'') (OTC BB:AVXL.OB) today announced the appointment of Alison Ayers to its Board of Directors. Ms. Ayers is currently the Worldwide Commercial Head for Oncology at Pfizer, with responsibility for Pfizer's oncology portfolio, which includes more than 20 drug candidates... - May 23, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences Corp. achieved significant development of its lead drug candidates and growth of its management and scientific teams during 2007. - January 24, 2008 - Anavex Life Sciences Corp.

ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies. - January 16, 2008 - Anavex Life Sciences Corp.

Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits. - January 16, 2008 - Anavex Life Sciences Corp.

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL - News) announces the appointment of Dr. Cameron Durrant to its Board of Directors. - January 16, 2008 - Anavex Life Sciences Corp.

Company Executives Offer “Crystal Ball” Predictions. VP of Research Discusses Need for New Approaches in Anti-Infectives. - November 22, 2007 - NovaBay Pharmaceuticals, Inc.

IRG to Communicate the Company’s Clinical Development Programs - November 21, 2007 - NovaBay Pharmaceuticals, Inc.

New Life Scientific, Inc. (OTCBB: NWLS), a company which specializes in the development of new biotechnology products and pharmaceuticals, announced today that it has transferred marketing rights to Atlan International(OTC: ATLI) of license agreement for two platform technologies (patent pending) that... - February 27, 2007 - New Life Scientific, Inc.

Pharma Trials International, Inc. a subsidiary of New Life Scientific, Inc. (OTCBB: NWLS), specializes in providing clinical trial services, market research, and services to enable pharmaceutical, biotech and medical device companies worldwide to conduct research and to obtain regulatory approval of... - February 01, 2007 - New Life Scientific, Inc.

After very successful pre-clinical trials for its lead product ‘Minozac,’ Neuromedix is planning further work on this promising Alzheimer’s treatment. - December 01, 2006 - Neuromedix Inc.

New Life Scientific, Inc (NWLS) a developmental biotech company whose core focus is to develop and commercialize novel biotech/pharmaceutical products including vaccines and stem cell based treatment modalities and to expand through our own research, collaborations, acquisitions and in-licensing, announced... - September 01, 2006 - New Life Scientific, Inc.

New Life Scientific, Inc (NWLS), today announced that at the special meeting of the Board of Directors a decision was made to re-evaluate its current progress and review its future options being considered include reviewing opportunities to acquire, license, and/or joint venture various medical, pharmaceutical,... - April 11, 2006 - New Life Scientific, Inc.

New Life Scientific, Inc. (OTCBB:NWLF - News) and Telomolecular Corp, have announced a strategic alliance to develop products that treat aging and age-related disease. New Life Scientific, Inc a company engaged in developing pharmaceutical products as well as managing PharmaTrials International (PTI),... - December 05, 2005 - New Life Scientific, Inc.